Form 6-K BitVentures Ltd For: Jan 31
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-40238
BitVentures Limited
Level 15, AIA Central, No.1 Connaught Road Central
Central, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
On January 7, 2026 New York Time, BitVentures Limited (“BitVentures” or the “Company”) (NASDAQ: BVC) today announced that the Third Amended and Restated Memorandum and Articles of Association of the Company became effective on December 29, 2025, following the shareholders’ approval by special resolution at the Extraordinary General Meeting. A copy of the Third Amended and Restated Memorandum and Articles of Association of the Company is filed herewith as Exhibit 3.1 and is incorporated herein by reference.
As a result of this Extraordinary General Meeting, an updated description of securities reflecting the updated rights and privileges as set out in the Third Amended and Restated Memorandum and Articles of Association of the Company is attached hereto as Exhibit 99.1.
Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
BitVentures Limited |
||
|
By: |
/s/ Lawrence Lok |
|
|
Name: |
Lawrence Lok |
|
|
Title: |
Chairman and CEO |
|
Date: January 7, 2026 New York Time
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SAMARITAN'S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK
- Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
- Salomon Unfolds the Next Chapter of ROAD TO THE FUTURE in Shanghai
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
